Please assess the completion status of the following clinical trial:

Trial Title: Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Woman, 18 years old or upper.~* Patient with advanced breast cancer with human epidermal growth factor receptor 2 (HER 2) positive histologically confirmed. The criteria for positivity HER 2 are:~  1. immuno-histochemistry (IHC) 3+ (\>10% of tumor cells with complete and intense membrane staining)~ 2. IHC 2+ with fluorescent in situ hybridization (FISH) / Chromogenic in situ hybridization (CISH) / silver-enhanced in situ hybridization (SISH) + for HER 2 amplification (\*)~ 3. FISH / CISH / SISH + for HER 2 amplification (\*) (\*) Defined as the ratio of copies of HER 2/neu and copies of centromere of chromosome 17 (CEP17)\> 2.2, or a number of copies of HER 2/neu\> 6, as per local laboratory criteria.~* Patient receiving trastuzumab with or without chemotherapy or hormonal therapy for at least 4 months.~* No evidence of disease progression (clinical and / or radiological) for at least 4 months before inclusion in the study and with a life expectancy of at least 3 months.~* Adequate performance status: Eastern Cooperative Oncology Group (ECOG) \<2.~* Adequate bone marrow function, liver and kidney~* Proper cardiac function (LVEF within normal limits the center, measured by echocardiography or MUGA).~* The patient must have been informed of the study and must sign and date informed consent document for entry into the trial.~* The patient must be willing and able to comply with study procedures and be available to answer the study questionnaires.~Exclusion Criteria:~* Patients with no advanced breast cancer.~* Breast cancer patients with tumors HER 2-negative.~* The patient has another active malignancy other than breast adenocarcinoma; are excluded the non-melanoma skin cancer or any other properly treated in situ neoplasia. Patients with a history of malignancy, if they bear\> 5 years without evidence of disease could be included.~* The patient has uncontrolled brain metastases.~* Concomitant administration, or in the 4 weeks prior to study entry, of other experimental treatment.~* Known hypersensitivity to trastuzumab or to any of its components.~* Patients with severe dyspnea at rest or requiring supplemental oxygen.~* Heart disease or serious medical pathological prevent trastuzumab administration: documented history of congestive cardiac insufficiency (CCI), high-risk arrhythmias uncontrolled angina requiring medication, clinically significant valvular disease, history of myocardial infarction or evidence of transmural infarction on ECG or hypertension poorly controlled.~* Presence of any concomitant serious systemic disease that is incompatible with the study (at the discretion of the investigator).~* The patient is pregnant or lactating. Women of childbearing potential should undergo pregnancy testing blood or urine within 14 days prior to inclusion as institutional rules and use a non-hormonal contraceptive suitable: intrauterine device, barrier method (condom or diaphragm) also used in conjunction with spermicidal cream, total abstinence or surgical sterilization, during treatment with the study drugs and for 6 months following the end of treatment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: T-IV + T-SC vial + T-SC device (Type: EXPERIMENTAL): Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with vial (Injectable Solution) x 2 cycles, followed by 600mg of T-SC with single injection device (SID) x 2 cycles.
- Arm B: T-IV + T-SC device + T-SC vial (Type: EXPERIMENTAL): Trastuzumab intravenous (T-IV) x 1 cycle (usual dose of Trastuzumab), followed by 600mg of Trastuzumab Subcutaneous (T-SC) with single injection device (SID) x 2 cycles, followed by 600mg of T-SC with vial (Injectable Solution) x 2 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete